Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer? | Journal of Clinical Oncology
Intermittent Relacorilant With Nab-Paclitaxel Leads to OS Benefit in Pretreated Ovarian Cancer Population
Relacorilant regimen prolongs survival in recurrent platinum-resistant ovarian cancer
Addition of Relacorilant to Nab-Paclitaxel Improves
Encouraging results of relacorilant in ovarian cancer - Medical Conferences
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers | British Journal of Cancer
EP305/#335 Short-course of nab-paclitaxel plus carboplatin in first-line advanced ovarian cancer treatment: a multicenter, nonrandomized controlled, phase II study | International Journal of Gynecologic Cancer
Frontiers | Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
Adding Relacorilant to Nab-Paclitaxel May Benefit Some Patients With Ovarian Cancer - Cancer Therapy Advisor
![PDF] Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2b8243d0cd6da82dad4e6b60a9fd68978010e599/5-Table1-1.png "PDF] Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer | Semantic Scholar")
PDF] Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer | Semantic Scholar
Nab-paclitaxel in Ovarian Cancer - ppt download
Antitumor effects of nab-paclitaxel with different regimens in... | Download Scientific Diagram
Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer? | Journal of Clinical Oncology
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
Relacorilant in PROC - Slideset Download - Clinical Oncology 2022 | CCO
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives | Archives of Gynecology and Obstetrics
Paclitaxel Injection 100mg Paclitax Nab | Rizochem Pharmaceuticals
Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Surviv
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer | BioSpace
ROSELLA: A study of relacorilant in combination with nab-paclitaxel in platinum resistant ovarian cancer | Target Ovarian Cancer
Addition of Relacorilant to Nab-paclitaxel in Recurrent, Platinum-Resistant Ovarian Cancer - The ASCO Post
Nab-Paclitaxel: A Novel Formulation of Taxane for Treatment of Breast Cancer - Prakash Vishnu, Vivek Roy, 2010
